The peptide synthesis market is projected to secure a valuation of US$ 520.0 million in 2023 and is rising to US$ 1.1 billion by 2033. The market is predicted at a CAGR of 8% during the forecast period.
Peptide Synthesis Market – Driving Factors
Increasing Medication Issues Decline Market Growth
Rising chemical-produced medications and regulatory issues are the factors that may restrain market growth. The European Medicines Agency and Food and Drug Administration are also at odds in regulating the approval of medications based on the peptide. The lack of consistent rules and difficulty in permitting therapeutic peptides limit market growth.
How do Peptide Synthesis Manufacturers Drive Market Opportunities?
Advanced medicine and limited side effects increase the demand for peptide synthesis and market opportunities during the forecast period. The growing investment and key healthcare manufacturers pushing the investment in personalized medicine are driving market expansion. Growing technology of automated injection of various chemicals, such as membrane enhanced and ligand synthesis, is increasing the adoption of peptide synthesis.
Growing healthcare infrastructure and improvements in medications are boosting market opportunities. Manufacturers are advancing customized medicine, and individualized therapy for patients is further increasing market opportunities. The development of proteomic analysis and methods of determining molecular profiles greatly contribute to expanding the market growth.
The adoption of proteomics to clarify pathomechanisms illness is propelling the market size. The European Union scientist announced the development of user-friendly electrochemical customized peptide synthesis in the ElectroMed project, a technology to detect the interaction between immune receptors and short peptides. This customized peptide synthesis is typically based on a microfluidic multiplexing system.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 8% |
| Market Valuation (2023) | US$ 520 million |
| Market Valuation (2033) | US$ 1.1 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights, the global peptide synthesis market is predicted at a healthy 8% CAGR during the forecast period. Historically, the market registered a CAGR of 11.5% between 2017 and 2022.
The market is estimated to reach US$ 1.1 billion during the forecast period. Historically, the market stood at US$ 460.0 million from 2017 to 2022.
Peptide Synthesis Market:
| Attributes | Peptide Synthesis Market |
|---|---|
| CAGR (2023 to 2033) | 8% |
| Value (2023) | US$ 520.0 million |
| Value (2033) | US$ 1.1 billion |
| Trends | The increasing biotech sector, advanced therapy, and investment in personalized medicine are driving market expansion. |
| Opportunities | Increasing automated injection technology and development of proteomics driving market opportunities. |
Peptide Therapeutics Market:
| Attributes | Peptide Therapeutics Market |
|---|---|
| CAGR (2023 to 2033) | 8% |
| Value (2023) | US$ 40.49 billion |
| Value (2033) | US$ 87.41 billion |
| Trends | Growing demand for immune peptides and developed infrastructure. |
| Opportunities | Governments initiative, growing advanced therapy, and research and development activities. |
Custom Peptide Synthesis Services Market:
| Attributes | Custom Peptide Synthesis Services Market |
|---|---|
| CAGR (2023 to 2033) | 7% |
| Value (2023) | US$ 571.41 million |
| Value (2033) | US$ 1,124.05 million |
| Trends | Growing research activities and investment in peptide synthesis. |
| Opportunities | Rising healthcare services and research activities to design drugs and vaccines |
Principal Consultant
| Segments | Product and Services |
|---|---|
| Top Category | Reagents |
| Historic CAGR | 11.4% |
| Forecast CAGR | 7.8% |
| Segments | End Use |
|---|---|
| Top Category | Pharmaceuticals & Biotechnology Companies |
| Historic CAGR | 11.1% |
| Forecast CAGR | 7.6% |
Based on the product and services segment, the reagents category holds a maximum CAGR of 7.8% during the forecast period. The adoption of reagents widely in laboratories, pharmaceutical manufacturing, and research & development activities is driving the market growth.
Apart from reagents, coupling agents are also widely used by various chemical laboratories to identify or research a particular substance. These growing demand factors are flourishing the market expansion. Historically, the reagents captured a CAGR of 11.4% between 2017 and 2022.
Based on technology, the segment is divided into solid-phase peptide synthesis, solution-phase peptide synthesis, and membrane-enhanced peptide synthesis technology. Pharmaceuticals & biotechnology sectors use different technology to develop a certain product type. Therefore, chemical synthesis is the commonly used process for peptide production in these industries.
This process has influenced the adoption of enzymatic technology. Though, the changing environment and manufacturing caps on industries slow down the growth of this segment. The process of chemical synthesis triggers pollution and environmental risks.
Based on end use, there are several industries like CDMOs & CROs, pharmaceuticals & biotechnology, academics & research institutions, and others. Pharmaceuticals and biotechnology are leading the segment by securing a CAGR of 7.6% during the forecast period. The adoption of peptide synthesis for the development of therapeutic in pharmaceuticals & biotechnology is bolstering the market growth.
The growing demand for drugs and vaccines with peptide synthesis is driving the pharmaceutical sector. For instance, AstraZeneca launched new advanced peptide therapy and next-generation medicine through research and development programs. FDA-approved Rybelsus tablets for diabetes type 2 patients. Historically, pharmaceuticals & biotechnology secured a CAGR of 11.1% between 2017 and 2020.
| Countries | United States |
|---|---|
| CAGR (2017 to 2022) | 13.5% |
| CAGR (2023 to 2023) | 7.8% |
| Valuation (2023 to 2033) | US$ 398.6 million |
| Countries | United Kingdom |
|---|---|
| CAGR (2017 to 2022) | 12.5% |
| CAGR (2023 to 2023) | 7.1% |
| Valuation (2023 to 2033) | US$ 47.3 million |
| Countries | China |
|---|---|
| CAGR (2017 to 2022) | 13.1% |
| CAGR (2023 to 2023) | 7.4% |
| Valuation (2023 to 2033) | US$ 80.7 million |
| Countries | Japan |
|---|---|
| CAGR (2017 to 2022) | 12% |
| CAGR (2023 to 2023) | 6.5% |
| Valuation (2023 to 2033) | US$ 66 million |
| Countries | South Korea |
|---|---|
| CAGR (2017 to 2022) | 11.1% |
| CAGR (2023 to 2023) | 6% |
| Valuation (2023 to 2033) | US$ 39.6 million |
The United States dominates the global market by securing a CAGR of 7.8% with a valuation of US$ 398.6 million during the forecast period. The rise in chronic patients adopting peptide-based vaccines and drugs propels the United States market. In 2022, according to the American Cancer Society, around 1.9 million new cancer cases grew in the United States. Cancer is a prior deadly disease after a heart attack in the United States.
Increasing rates of diabetes patients, inactive lifestyles, and obesity are fueling the United States peptide synthesis market. In addition, the development of modern drugs and increasing government investment are expanding the United States market. Historically, the United States secured a CAGR of 13.5% between 2017 and 2022.
The United Kingdom captured a CAGR of 7.1% with a valuation of US$ 47.3 million during the forecast period. Developing advanced chemical and organic peptides with a high investment in research and development activities is expanding the United States market. In addition, the growing risk of chronic diseases and the presence of the biochemical industry is surging the United States peptide synthesis market.
The rising urbanization, healthcare infrastructure, and manufacturing industry are expanding the market. Historically, the United Kingdom secured a CAGR of 12.5% between 2017 and 2020.
China is contributing a CAGR of 7.4% with a valuation of US$ 80.7 million during the forecast period. Increasing research and development investment and the biotech sector are flourishing in China's peptide synthesis market growth. In addition, rising demand for the minimal cost of raw materials and the adoption of advanced therapy is further increasing the China market expansion.
Lack of proper diet, a sedentary lifestyle, and low physical activities result in chronic diseases, increasing the demand for peptide synthesis. Moreover, the present prominent players and the development of new technologies in peptide synthesis are driving China market. Historically, China secured a CAGR of 13.1% between 2017 and 2020.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The multiple established companies and the presence of key players consolidate the market. In addition, due to the modernization of medical research and development projects and rising pharmaceutical manufacturing, the key competitors focus on providing effective products and services.
By adopting several marketing tactics and deep market research, the market players are increasing the sales of peptide synthesis products. Their marketing tactics are mergers, acquisitions, collaborations, and partnerships.
Recent Developments in the Market:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, Canada, Germany, United Kingdom., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Northern Africa, South Africa, and Türkiye |
| Key Segments Covered | Product and Services, Technology, End Use, Region |
| Key Companies Profiled | GenScript Biotech Corporation; Bachem Holding AG; Thermo Fisher Scientific Inc; Merck KGaA; Kaneka Corporation |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market in 2023 is valued at US$ 520.0 million.
By 2033, the market will expand at a 8% CAGR.
By 2033, the market will reach US$ 1.1 billion.
From 2018 to 2022, the global market exhibited a 11.5% CAGR.
Merck KGaA, Kaneka Corporation
1. Executive Summary | Peptide Synthesis Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product and Service 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product and Service, 2017 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product and Service, 2023 to 2033 5.3.1. Reagents 5.3.2. Equipment 5.3.3. Services 5.4. Y-o-Y Growth Trend Analysis By Product and Service, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Product and Service, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Technology 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2017 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033 6.3.1. Solid-Phase Peptide Synthesis 6.3.2. Solution-Phase Peptide Synthesis 6.3.3. Hybrid & Recombinant Technology 6.4. Y-o-Y Growth Trend Analysis By Technology, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End Use 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End Use , 2017 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use , 2023 to 2033 7.3.1. Pharmaceuticals & Biotechnology Companies 7.3.2. CDMOs & CROs 7.3.3. Academics & Research Institutes 7.4. Y-o-Y Growth Trend Analysis By End Use , 2017 to 2022 7.5. Absolute $ Opportunity Analysis By End Use , 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Product and Service 9.2.3. By Technology 9.2.4. By End Use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product and Service 9.3.3. By Technology 9.3.4. By End Use 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product and Service 10.2.3. By Technology 10.2.4. By End Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product and Service 10.3.3. By Technology 10.3.4. By End Use 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Product and Service 11.2.3. By Technology 11.2.4. By End Use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product and Service 11.3.3. By Technology 11.3.4. By End Use 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Thailand 12.2.1.5. Singapore 12.2.1.6. Australia 12.2.1.7. Rest of Asia Pacific 12.2.2. By Product and Service 12.2.3. By Technology 12.2.4. By End Use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product and Service 12.3.3. By Technology 12.3.4. By End Use 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Product and Service 13.2.3. By Technology 13.2.4. By End Use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product and Service 13.3.3. By Technology 13.3.4. By End Use 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Product and Service 14.1.2.2. By Technology 14.1.2.3. By End Use 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Product and Service 14.2.2.2. By Technology 14.2.2.3. By End Use 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Product and Service 14.3.2.2. By Technology 14.3.2.3. By End Use 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Product and Service 14.4.2.2. By Technology 14.4.2.3. By End Use 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Product and Service 14.5.2.2. By Technology 14.5.2.3. By End Use 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Product and Service 14.6.2.2. By Technology 14.6.2.3. By End Use 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Product and Service 14.7.2.2. By Technology 14.7.2.3. By End Use 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Product and Service 14.8.2.2. By Technology 14.8.2.3. By End Use 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Product and Service 14.9.2.2. By Technology 14.9.2.3. By End Use 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Product and Service 14.10.2.2. By Technology 14.10.2.3. By End Use 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Product and Service 14.11.2.2. By Technology 14.11.2.3. By End Use 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Product and Service 14.12.2.2. By Technology 14.12.2.3. By End Use 14.13. Thailand 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Product and Service 14.13.2.2. By Technology 14.13.2.3. By End Use 14.14. Singapore 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Product and Service 14.14.2.2. By Technology 14.14.2.3. By End Use 14.15. Australia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Product and Service 14.15.2.2. By Technology 14.15.2.3. By End Use 14.16. GCC Countries 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Product and Service 14.16.2.2. By Technology 14.16.2.3. By End Use 14.17. South Africa 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Product and Service 14.17.2.2. By Technology 14.17.2.3. By End Use 14.18. Israel 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Product and Service 14.18.2.2. By Technology 14.18.2.3. By End Use 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Product and Service 15.3.3. By Technology 15.3.4. By End Use 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. GenScript Biotech Corporation 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Bachem Holding AG 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Thermo Fisher Scientific Inc. 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Merck KGaA 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Kaneka Corporation 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Biotage AB 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Syngene International Limited 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Mesa Laboratories, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Cem Corporation 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Proteogenix 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Peptide Synthesis Market
